Developer docs
API playgroundTry for free, no card

Search company profiles

Altos Labs

Full company profile

uuid00003vp

Namestring
Altos Labs
Legal namestring
Altos Labs, Inc.
Websiteurl
altoslabs.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cellular rejuvenation research, epigenetic reprogramming therapeutics, biotechnology drug discovery, aging disease reversal, computational biology platform
Industry6 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services5415
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Services-Computer Integrated Systems Design7373
  • Electronic Computers3571
Product category
Biotechnology Research
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue R&D biotech
TypeLicensing Royalties
Description

Altos Labs is a private, pre-revenue biotechnology company focused on cellular rejuvenation research. Revenue generation is not yet applicable as the company is still in the discovery, preclinical, and translational research phase, building medicines that will eventually be commercialized through drug development pipelines or partnerships.

altoslabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Altos Labs is a pre-revenue biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience and reverse disease. Its core offering is a research and drug discovery platform built on partial epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), operationalized through three Institutes of Science, an Institute of Medicine, and an Institute of Computation. Future commercialization is expected through biopharma partnerships, licensing, and internal drug development pipelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 30% extension of mouse lifespan through partial cellular reprogramming in preclinical studies
+2 more records
Product overview1 text field

Altos Labs is a single platform company — not a multi-product SaaS suite — built around one core therapeutic platform: cellular rejuvenation programming to restore cell health and resilience and reverse disease, injury, and the disabilities that occur throughout life. The platform is organized as a hub-and-spoke architecture comprising three Institutes of Science (the Bay Area Institute of Science in Redwood City, CA; the San Diego Institute of Science; and the Cambridge Institute of Science in the UK) that pursue deep biological questions on rejuvenation and reprogramming, a translational Institute of Medicine (IoM) led by Dolo Diaz and Joan Mannick that converts discoveries into medicines, and an Institute of Computation (IoC) led by Hana El-Samad that builds multi-scale generative AI models to decode cell health. Together, the Institute of Computation provides AI/ML infrastructure and models, the Institutes of Science generate biological hypotheses and pre-clinical data, and the Institute of Medicine develops transformative therapeutics — all feeding the cellular rejuvenation programming core platform. Founding science is rooted in Shinya Yamanaka's induced pluripotent stem cell research and Juan Carlos Izpisua Belmonte's partial reprogramming breakthroughs.

Product and service6 records
1Cellular Rejuvenation Programming Platform
CategoryBiotechnology Research Platform
Description

Foundational scientific and therapeutic platform focused on restoring cell health and resilience through partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). Resets cells to a state more resilient to stressors while retaining cell identity and youthful functions. Forms the core of Altos Labs' pipeline for future therapeutic development.

2Bay Area Institute of Science
CategoryResearch Institute
Description

One of three Altos Labs Institutes of Science, located in Redwood City, CA (San Francisco Bay Area). Directed by Jodi Nunnari, PhD, with principal investigators working on mitochondrial biology, microproteome (Jin Chen), cognitive dysfunction (Susanna Rosi), integrated stress response (Mauro Costa-Mattioli), and homeostasis (Adam Frost).

3San Diego Institute of Science
CategoryResearch Institute
Description

Altos Labs' San Diego-based Institute of Science conducting research on genome technologies, bioengineering, single-cell sequencing, stem cell aging, and nuclear proteostasis. Principal investigators include Kun Zhang (genomics and bioengineering) and Pura Muñoz-Cánoves (stem cell aging), with Zachary Levine focusing on promiscuous protein assemblies.

4Cambridge Institute of Science (UK)
CategoryResearch Institute
Description

Altos Labs' United Kingdom Institute of Science located in Cambridge, directed by Wolf Reik, MD. Research focuses on epigenetic reprogramming in development and aging, nuclear envelope dysfunction (Delphine Larrieu), cellular senescence and reprogramming (Manuel Serrano), neurodegeneration and the Unfolded Protein Response (Giovanna Mallucci), adult CNS stem cell aging (Robin Franklin), and histone/DNA methylation changes (Ken Raj).

5Institute of Medicine (IoM)
CategoryDrug Development Institute
Description

Altos Labs' translational institute that captures knowledge about cell health and programming to develop transformative medicines. Led by Dolo Diaz, PhD (Global Head and SVP of Drug Discovery and Development Sciences), Joan Mannick, MD (SVP, CMO and Head of Product Development), and Sharon Wang, PhD (Global Head and SVP of Technical Operations). Translates breakthrough science into breakthrough medicines.

6Institute of Computation (IoC)
CategoryAI/ML Computation Institute
Description

Altos Labs' newly formed scientific institute focused on building computational models that decode the language of biological resilience at the cell, organ, and organism levels. Directed by Hana El-Samad, PhD. Founding Principal Investigators Morgan Levine (VP, Computation, formerly Yale) and Simone Bianco (VP, Computation, formerly IBM Almaden Research Center); Bikash Sabata serves as VP of Software and Platforms. Leverages AI/ML to program cells to a state of resilience.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

British biotech Cyclana Bio secured $6.6 million in pre-seed funding and was founded by former Altos Labs scientists. It develops therapies for chronic inflammation-driven diseases starting with endometriosis, creating tissue models to improve drug discovery.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Simone Bianco, now VP of Computation at Altos Labs, previously was a research staff member and manager of Functional Genomics and Cellular Engineering at IBM Almaden Research Center, providing talent and expertise transfer into Altos's Institute of Computation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hana El-Samad, SVP and Director of Institute of Computation, was previously the Kuo Family Endowed Professor at UCSF. Multiple principal investigators (Adam Frost, Susanna Rosi) were recruited from UCSF, forming a deep academic talent pipeline.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Morgan Levine, VP of Computation, was previously a ladder-rank professor at Yale School of Medicine. Zachary Levine, PI at San Diego Institute, continues as adjunct faculty at Yale. Yale School of Medicine is a source of biological clocks and aging expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Juan Carlos Izpisua Belmonte, Altos's Founding Scientist and SVP, was previously the Roger Guillemin Chair and Professor at the Salk Institute. Travis Berggren, VP of Scientific Operations, joined from the Salk Institute where he was Executive Director of Research Operations.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Alphabet-backed life sciences company focused on aging and longevity, with an academic-style research model and deep funding. Directly comparable to Altos in mission, scientific posture, and capital intensity, though Calico's therapeutic programs are less publicly disclosed.

TypeDirect peer
Description

Cellular rejuvenation biotech pursuing partial reprogramming and related gene therapy approaches to age-related disease. Highly comparable to Altos on platform approach and target indications, though smaller in capital base and institute footprint.

TypeDirect peer
Description

Epigenetic reprogramming biotech focused on restoring youthful function in aged cells, also backed by tech-billionaire capital (including Jeff Bezos). Closely comparable to Altos on core platform science (Yamanaka factors) and longevity focus.

4Turn Biotechnologies
TypeDirect peer
Description

Clinical-stage epigenetic reprogramming company developing mRNA-based OSKM delivery to restore youthful cellular function. Comparable to Altos on core reprogramming science, with a more clinical-stage asset profile.

TypeDirect peer
Description

Clinical-stage biotech developing senolytic therapies to clear senescent cells for age-related disease. Comparable to Altos on aging-therapeutics market, with differentiated mechanism (senolytics vs. partial reprogramming).

TypeBroad incumbent
Description

AI-driven drug discovery company with a longevity-focused pipeline and proprietary Pharma.AI platform. Comparable to Altos on the AI/ML-meets-aging intersection, though Insilico is broader and more clinically advanced across multiple therapeutic areas.

TypeBroad incumbent
Description

Publicly traded AI-driven biotech combining high-throughput biology with ML for drug discovery. Comparable to Altos on the integration of large-scale data and AI/ML in pharmaceutical R&D, though Recursion is platform-agnostic rather than aging-focused.

TypeOthers
Description

Saudi-backed non-profit foundation funding geroscience and longevity research globally. Comparable to Altos as a funder in the longevity space and a potential capital or partnership counterparty rather than a direct therapeutic competitor.

TypeEmerging player
Description

Biotech developing therapeutics for neurodegeneration with strong talent ties to the Bay Area biotech ecosystem (Altos's Dolo Diaz joined from Denali). Comparable to Altos on neurodegenerative disease focus and translational model, though Denali is more clinical-stage and broader in scope.

TypeEmerging player
Description

Veterinary longevity biotech developing drugs to extend healthy lifespan in dogs as a stepping stone to human therapies. Comparable to Altos on aging therapeutics mission, with a differentiated companion-animal go-to-market that de-risks translation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altos Labs

Biotechnology Researchaltoslabs.com

Altos Labs firmographics

Firmographics
Name
Altos Labs
Legal name
Altos Labs, Inc.
Website
https://altoslabs.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Altos Labs industry classification

Industry
Product category
Biotechnology Research
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (5415)
SIC
Laboratory Analytical Instruments (3826), Services-Computer Integrated Systems Design (7373), Electronic Computers (3571)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cellular rejuvenation research
  • Epigenetic reprogramming therapeutics
  • Biotechnology drug discovery
  • Aging disease reversal
  • Computational biology platform

Where Altos Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Altos Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue R&D biotech: Altos Labs is a private, pre-revenue biotechnology company focused on cellular rejuvenation research. Revenue generation is not yet applicable as the company is still in the discovery, preclinical, and translational research phase, building medicines that will eventually be commercialized through drug development pipelines or partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Altos Labs product offering

Product offering

Core offering

Altos Labs is a pre-revenue biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience and reverse disease. Its core offering is a research and drug discovery platform built on partial epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), operationalized through three Institutes of Science, an Institute of Medicine, and an Institute of Computation. Future commercialization is expected through biopharma partnerships, licensing, and internal drug development pipelines.

Product overview

Altos Labs is a single platform company — not a multi-product SaaS suite — built around one core therapeutic platform: cellular rejuvenation programming to restore cell health and resilience and reverse disease, injury, and the disabilities that occur throughout life. The platform is organized as a hub-and-spoke architecture comprising three Institutes of Science (the Bay Area Institute of Science in Redwood City, CA; the San Diego Institute of Science; and the Cambridge Institute of Science in the UK) that pursue deep biological questions on rejuvenation and reprogramming, a translational Institute of Medicine (IoM) led by Dolo Diaz and Joan Mannick that converts discoveries into medicines, and an Institute of Computation (IoC) led by Hana El-Samad that builds multi-scale generative AI models to decode cell health. Together, the Institute of Computation provides AI/ML infrastructure and models, the Institutes of Science generate biological hypotheses and pre-clinical data, and the Institute of Medicine develops transformative therapeutics — all feeding the cellular rejuvenation programming core platform. Founding science is rooted in Shinya Yamanaka's induced pluripotent stem cell research and Juan Carlos Izpisua Belmonte's partial reprogramming breakthroughs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cellular Rejuvenation Programming Platform Foundational scientific and therapeutic platform focused on restoring cell health and resilience through partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). Resets cells to a state more resilient to stressors while retaining cell identity and youthful functions. Forms the core of Altos Labs' pipeline for future therapeutic development.
  • Bay Area Institute of Science One of three Altos Labs Institutes of Science, located in Redwood City, CA (San Francisco Bay Area). Directed by Jodi Nunnari, PhD, with principal investigators working on mitochondrial biology, microproteome (Jin Chen), cognitive dysfunction (Susanna Rosi), integrated stress response (Mauro Costa-Mattioli), and homeostasis (Adam Frost).
  • San Diego Institute of Science Altos Labs' San Diego-based Institute of Science conducting research on genome technologies, bioengineering, single-cell sequencing, stem cell aging, and nuclear proteostasis. Principal investigators include Kun Zhang (genomics and bioengineering) and Pura Muñoz-Cánoves (stem cell aging), with Zachary Levine focusing on promiscuous protein assemblies.
  • Cambridge Institute of Science (UK) Altos Labs' United Kingdom Institute of Science located in Cambridge, directed by Wolf Reik, MD. Research focuses on epigenetic reprogramming in development and aging, nuclear envelope dysfunction (Delphine Larrieu), cellular senescence and reprogramming (Manuel Serrano), neurodegeneration and the Unfolded Protein Response (Giovanna Mallucci), adult CNS stem cell aging (Robin Franklin), and histone/DNA methylation changes (Ken Raj).
  • Institute of Medicine (IoM) Altos Labs' translational institute that captures knowledge about cell health and programming to develop transformative medicines. Led by Dolo Diaz, PhD (Global Head and SVP of Drug Discovery and Development Sciences), Joan Mannick, MD (SVP, CMO and Head of Product Development), and Sharon Wang, PhD (Global Head and SVP of Technical Operations). Translates breakthrough science into breakthrough medicines.
  • Institute of Computation (IoC) Altos Labs' newly formed scientific institute focused on building computational models that decode the language of biological resilience at the cell, organ, and organism levels. Directed by Hana El-Samad, PhD. Founding Principal Investigators Morgan Levine (VP, Computation, formerly Yale) and Simone Bianco (VP, Computation, formerly IBM Almaden Research Center); Bikash Sabata serves as VP of Software and Platforms. Leverages AI/ML to program cells to a state of resilience.

Quantifiable outcome

  • Up to 30% extension of mouse lifespan through partial cellular reprogramming in preclinical studies
  • +2 more outcomes

Companies that use Altos Labs

Customer profile

Ideal customer profiles2 records

Altos Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Altos Labs partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Cyclana BiominorStrategic or Co-development Partner · 30 October 2025British biotech Cyclana Bio secured $6.6 million in pre-seed funding and was founded by former Altos Labs scientists. It develops therapies for chronic inflammation-driven diseases starting with endometriosis, creating tissue models to improve drug discovery.
  • IBM Almaden Research CenterminorStrategic or Co-development PartnerSimone Bianco, now VP of Computation at Altos Labs, previously was a research staff member and manager of Functional Genomics and Cellular Engineering at IBM Almaden Research Center, providing talent and expertise transfer into Altos's Institute of Computation.
  • UCSF (University of California, San Francisco)coreStrategic or Co-development PartnerHana El-Samad, SVP and Director of Institute of Computation, was previously the Kuo Family Endowed Professor at UCSF. Multiple principal investigators (Adam Frost, Susanna Rosi) were recruited from UCSF, forming a deep academic talent pipeline.
  • Yale University School of MedicinecoreStrategic or Co-development PartnerMorgan Levine, VP of Computation, was previously a ladder-rank professor at Yale School of Medicine. Zachary Levine, PI at San Diego Institute, continues as adjunct faculty at Yale. Yale School of Medicine is a source of biological clocks and aging expertise.
  • Salk Institute for Biological StudiescoreStrategic or Co-development PartnerJuan Carlos Izpisua Belmonte, Altos's Founding Scientist and SVP, was previously the Roger Guillemin Chair and Professor at the Salk Institute. Travis Berggren, VP of Scientific Operations, joined from the Salk Institute where he was Executive Director of Research Operations.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Altos Labs competitors and assessment

Company assessment

Direct peers

  • Calico Labs: Alphabet-backed life sciences company focused on aging and longevity, with an academic-style research model and deep funding. Directly comparable to Altos in mission, scientific posture, and capital intensity, though Calico's therapeutic programs are less publicly disclosed.
  • Life Biosciences: Cellular rejuvenation biotech pursuing partial reprogramming and related gene therapy approaches to age-related disease. Highly comparable to Altos on platform approach and target indications, though smaller in capital base and institute footprint.
  • NewLimit: Epigenetic reprogramming biotech focused on restoring youthful function in aged cells, also backed by tech-billionaire capital (including Jeff Bezos). Closely comparable to Altos on core platform science (Yamanaka factors) and longevity focus.
  • Turn Biotechnologies: Clinical-stage epigenetic reprogramming company developing mRNA-based OSKM delivery to restore youthful cellular function. Comparable to Altos on core reprogramming science, with a more clinical-stage asset profile.
  • Unity Biotechnology: Clinical-stage biotech developing senolytic therapies to clear senescent cells for age-related disease. Comparable to Altos on aging-therapeutics market, with differentiated mechanism (senolytics vs. partial reprogramming).

Broad incumbents

  • Insilico Medicine: AI-driven drug discovery company with a longevity-focused pipeline and proprietary Pharma.AI platform. Comparable to Altos on the AI/ML-meets-aging intersection, though Insilico is broader and more clinically advanced across multiple therapeutic areas.
  • Recursion Pharmaceuticals: Publicly traded AI-driven biotech combining high-throughput biology with ML for drug discovery. Comparable to Altos on the integration of large-scale data and AI/ML in pharmaceutical R&D, though Recursion is platform-agnostic rather than aging-focused.

Others

  • Hevolution Foundation: Saudi-backed non-profit foundation funding geroscience and longevity research globally. Comparable to Altos as a funder in the longevity space and a potential capital or partnership counterparty rather than a direct therapeutic competitor.

Emerging players

  • Denali Therapeutics: Biotech developing therapeutics for neurodegeneration with strong talent ties to the Bay Area biotech ecosystem (Altos's Dolo Diaz joined from Denali). Comparable to Altos on neurodegenerative disease focus and translational model, though Denali is more clinical-stage and broader in scope.
  • Loyal for Dogs: Veterinary longevity biotech developing drugs to extend healthy lifespan in dogs as a stepping stone to human therapies. Comparable to Altos on aging therapeutics mission, with a differentiated companion-animal go-to-market that de-risks translation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Altos Labs social profiles

Digital presence

Altos Labs compliance and trust

Trust signal

Compliance2 records

Altos Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altos Labs leadership team

Management profile

Number of profiles

Profiles19 records

Altos Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altos Labs M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altos Labs

What does Altos Labs do?

Altos Labs is a pre-revenue biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience and reverse disease. Its core offering is a research and drug discovery platform built on partial epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), operationalized through three Institutes of Science, an Institute of Medicine, and an Institute of Computation. Future commercialization is expected through biopharma partnerships, licensing, and internal drug development pipelines.

Is Altos Labs a public or private company?

Altos Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Altos Labs founded?

Altos Labs was founded in 2022. It employs 501 to 1,000 people.

Where is Altos Labs based?

Altos Labs is headquartered in San Francisco, United States, in the North America region.

How does Altos Labs make money?

One revenue line is on record: pre-revenue R&D biotech.

Who are Altos Labs's main competitors?

Direct peers on record are Calico Labs, Life Biosciences, NewLimit, Turn Biotechnologies and Unity Biotechnology. Broad incumbents are Insilico Medicine and Recursion Pharmaceuticals. Hevolution Foundation is listed as an others. Emerging players are Denali Therapeutics and Loyal for Dogs.

Does Altos Labs have an API?

No public API is recorded for Altos Labs.

What industry is Altos Labs in?

Altos Labs's product category is Biotechnology Research. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver"1년 수명 얼마에 팔까"…불로장생에 작년에만 25조 뭉칫돈The anti-aging industry is expanding rapidly, with tech giants like OpenAI investing heavily and pharmaceutical companies partnering with biotech firms. Eli Lilly's GLP-1 drugs have boosted its market cap, and companies like Retro and Altos Labs are pursuing epigenetic reprogramming. The FDA does not recognize aging as a disease, so companies are targeting approved conditions first.Business & FinancialGlobal Longevity Biotech And Epigenetic Reprogramming Market Report 2026 Capture 12.9% CAGR As Altos Labs, Retro Biosciences, Newlimit And Life Biosciences Scale ReprogrammingThe global longevity biotech and epigenetic reprogramming market is projected to grow from $23.93 billion in 2025 to $27.11 billion in 2026, a 13.3% CAGR, reaching $44.05 billion by 2030. Life Biosciences received FDA clearance for its ER-100 therapy in January 2026, entering Phase 1 trials for optic neuropathies.ExameAltman, Zuckerberg e Bezos: como bilionários da tecnologia estão mudando a ciênciaTech billionaires are expanding medical research investments, including cancer, aging, AI, and neurodegenerative diseases. Specific figures include Altos Labs with $3 billion, Chan Zuckerberg Initiative with $4 billion, and Gates with $200 billion planned. Private funding raises questions about priorities and transparency.In VivoDo We Know Enough to Build Longevity Medicine? Church Says Yes, And The Field Is About to Find OutHarvard geneticist George Church argues we know enough biology to start building longevity medicine, citing first human data and a newly interested FDA. He is skeptical of heavy basic-research bets at Calico and Altos. The FDA will include aging in its next regulatory science priorities, but no approval pathway is defined yet.WebProNewsScientists Accelerate Cellular Reprogramming to Reverse Aging and Extend LifespanScientists are advancing cellular reprogramming to reverse aging, with companies like Altos Labs and Retro Biosciences investing heavily. Early animal data shows extended lifespan and reduced age-related decline, and some backers predict first approved therapies by 2026. Safety and regulatory hurdles remain key challenges.FierceBiotechLuma locks down 15-year, $410M fund for life science investmentsLuma Group closed its inaugural life sciences fund, LumaBio Fund I, at $410 million. The fund has invested in over 10 biotechs, including Character Biosciences and Altos Labs. One of its co-founded companies, Vaccine Company, was acquired by Eli Lilly for up to $1.55 billion earlier this year.The Times of IndiaBillionaires Jeff Bezos, Sam Altman and Peter Thiel are trying to cheat deathSilicon Valley billionaires including Jeff Bezos, Sam Altman, and Peter Thiel are heavily investing in longevity research and biotech firms such as Retro Biosciences and Altos Labs to extend human life. Concurrently, Zomato founder Deepinder Goyal is launching a wearable device called Temple to monitor metabolic states, contributing to a global market projected to grow from $27 billion in 2025 to $67 billion by 2035.TimeJuan Carlos Izpisua Belmonte Believes Aging May Come Down to a Cell's Identity CrisisJuan Carlos Izpisua Belmonte, co-founder of Altos Labs, advocates for partial cellular reprogramming to restore cell identity and address aging and related diseases. Building on 2025 findings that this technique rejuvenated cells in mice organs, Altos is now conducting transplantation tests to determine if the approach can improve organ function and expand the donor pool for humans.Les EchosLongévité : « Les milliardaires investissent dans ces technologies car ils ne supportent pas la perspective de leur propre mort »Jeff Bezos and Sam Altman have invested billions into biotechnology companies, specifically Altos Labs and Retro Biosciences, to explore cellular reprogramming and life extension technologies. This influx of capital highlights the emergence of longevity as a major economic sector attracting significant private investment.National GeographicAre We on the Brink of Ending Aging?In April 2026, Life Biosciences launched the first human clinical trial of ER-100, a cellular reprogramming therapy, injecting it into a glaucoma patient's eye at a Glendale, California facility as part of an FDA trial. The treatment, developed by Harvard Medical School's David Sinclair, aims to reverse aging by getting genes to turn back the clock on damaged cells, with the hope that it could eventually reverse aging altogether. The trial marks the latest development in a rapidly growing, billion-dollar anti-aging biotechnology race that includes Altos Labs, NewLimit, and Retro Biosciences, all pursuing similar cellular reprogramming approaches.